NeoStem, Inc. (NBS) Receives Two-Year $1.2 Million NIH Grant for First Clinical Study of VSEL Technology in Humans
From The QualityStocks Daily Blog for Micro-cap and Small-Cap Companies
November 20, 2012 - 12:26pm
NeoStem is a firm engaged in the fast growing cell therapy industry. This industry is expected to have a significant role in the future in the fight against chronic disease. The company’s contract development and manufacturing service business, Progenitor Cell Therapy LLC, supports the development of proprietary cell therapy products. The company today announced that [...]
Continue reading this article »Share This Article: